Monsanto India is a subsidiary of the Monsanto Company, US. The company has been catering to the Indian farmers for over 50 years through its seeds and agrochemicals business segments. The company dominates the market in these two business segments t... More
India Glycols Limited (IGL) is a leading producer of Ethlyene Glycol, Di-Ethyl Glycol, EO Deravatives and Heavy Glycol. The company also produces MEG (Mono Ethylene Glycol), an important intermediate for fibre manufacture. In Ethoxylates, it is the m... More
MONSANTO INDIA | INDIA GLYCOLS | MONSANTO INDIA/ INDIA GLYCOLS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 23.8 | 9.0 | 263.5% | View Chart |
P/BV | x | 5.4 | 1.2 | 452.3% | View Chart |
Dividend Yield | % | 2.2 | 1.6 | 139.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
MONSANTO INDIA Mar-19 |
INDIA GLYCOLS Mar-19 |
MONSANTO INDIA/ INDIA GLYCOLS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,358 | 620 | 541.7% | |
Low | Rs | 2,424 | 233 | 1,040.3% | |
Sales per share (Unadj.) | Rs | 387.9 | 1,084.2 | 35.8% | |
Earnings per share (Unadj.) | Rs | 87.9 | 42.8 | 205.1% | |
Cash flow per share (Unadj.) | Rs | 94.7 | 67.5 | 140.4% | |
Dividends per share (Unadj.) | Rs | 50.00 | 6.00 | 833.3% | |
Dividend yield (eoy) | % | 1.7 | 1.4 | 122.9% | |
Book value per share (Unadj.) | Rs | 409.6 | 310.9 | 131.7% | |
Shares outstanding (eoy) | m | 17.26 | 30.96 | 55.7% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 7.5 | 0.4 | 1,894.6% | |
Avg P/E ratio | x | 32.9 | 10.0 | 330.5% | |
P/CF ratio (eoy) | x | 30.5 | 6.3 | 482.9% | |
Price / Book Value ratio | x | 7.1 | 1.4 | 514.7% | |
Dividend payout | % | 56.9 | 14.0 | 406.2% | |
Avg Mkt Cap | Rs m | 49,899 | 13,203 | 377.9% | |
No. of employees | `000 | 0.3 | 1.3 | 19.0% | |
Total wages/salary | Rs m | 511 | 1,008 | 50.6% | |
Avg. sales/employee | Rs Th | 26,570.6 | 25,332.9 | 104.9% | |
Avg. wages/employee | Rs Th | 2,025.8 | 761.1 | 266.2% | |
Avg. net profit/employee | Rs Th | 6,018.3 | 1,000.8 | 601.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,696 | 33,566 | 19.9% | |
Other income | Rs m | 220 | 169 | 130.0% | |
Total revenues | Rs m | 6,916 | 33,735 | 20.5% | |
Gross profit | Rs m | 1,596 | 4,169 | 38.3% | |
Depreciation | Rs m | 118 | 762 | 15.5% | |
Interest | Rs m | 11 | 1,435 | 0.8% | |
Profit before tax | Rs m | 1,687 | 2,141 | 78.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | -10 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 170 | 805 | 21.1% | |
Profit after tax | Rs m | 1,517 | 1,326 | 114.4% | |
Gross profit margin | % | 23.8 | 12.4 | 191.9% | |
Effective tax rate | % | 10.1 | 37.6 | 26.8% | |
Net profit margin | % | 22.7 | 4.0 | 573.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,847 | 13,853 | 49.4% | |
Current liabilities | Rs m | 2,811 | 17,250 | 16.3% | |
Net working cap to sales | % | 60.3 | -10.1 | -595.6% | |
Current ratio | x | 2.4 | 0.8 | 303.3% | |
Inventory Days | Days | 153 | 70 | 217.6% | |
Debtors Days | Days | 57 | 35 | 162.0% | |
Net fixed assets | Rs m | 1,220 | 23,103 | 5.3% | |
Share capital | Rs m | 173 | 310 | 55.7% | |
"Free" reserves | Rs m | 6,896 | 9,317 | 74.0% | |
Net worth | Rs m | 7,069 | 9,626 | 73.4% | |
Long term debt | Rs m | 0 | 3,961 | 0.0% | |
Total assets | Rs m | 9,986 | 37,843 | 26.4% | |
Interest coverage | x | 150.3 | 2.5 | 6,030.3% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.7 | 0.9 | 75.6% | |
Return on assets | % | 15.3 | 7.3 | 209.7% | |
Return on equity | % | 21.5 | 13.8 | 155.7% | |
Return on capital | % | 24.0 | 26.2 | 91.5% | |
Exports to sales | % | 8.3 | 24.2 | 34.2% | |
Imports to sales | % | 19.0 | 46.5 | 40.8% | |
Exports (fob) | Rs m | 554 | 8,115 | 6.8% | |
Imports (cif) | Rs m | 1,273 | 15,622 | 8.1% | |
Fx inflow | Rs m | 554 | 8,631 | 6.4% | |
Fx outflow | Rs m | 1,430 | 16,858 | 8.5% | |
Net fx | Rs m | -876 | -8,227 | 10.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 141 | 1,471 | 9.6% | |
From Investments | Rs m | 709 | -1,281 | -55.3% | |
From Financial Activity | Rs m | -831 | 30 | -2,761.8% | |
Net Cashflow | Rs m | 19 | 219 | 8.6% |
Indian Promoters | % | 0.0 | 61.1 | - | |
Foreign collaborators | % | 72.1 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.5 | 2.0 | 125.0% | |
FIIs | % | 3.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.4 | 36.9 | 60.7% | |
Shareholders | 18,771 | 33,622 | 55.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.9 | - |
Compare MONSANTO INDIA With: KANORIA CHEMICALS BASF INDIA SOLAR INDUSTRIES PI INDUSTRIES ATUL
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended December 2019, INDIA GLYCOLS has posted a net profit of Rs 293 m (down 16.2% YoY). Sales on the other hand came in at Rs 15 bn (up 23.1% YoY). Read on for a complete analysis of INDIA GLYCOLS's quarterly results.
Here's an analysis of the annual report of INDIA GLYCOLS for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of INDIA GLYCOLS. Also includes updates on the valuation of INDIA GLYCOLS.
For the quarter ended June 2019, INDIA GLYCOLS has posted a net profit of Rs 388 m (down 8.1% YoY). Sales on the other hand came in at Rs 14 bn (up 25.8% YoY). Read on for a complete analysis of INDIA GLYCOLS's quarterly results.
For the quarter ended June 2019, MONSANTO INDIA has posted a net profit of Rs 760 m (up 15.1% YoY). Sales on the other hand came in at Rs 3 bn (up 10.1% YoY). Read on for a complete analysis of MONSANTO INDIA's quarterly results.
Here's an analysis of the annual report of MONSANTO INDIA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of MONSANTO INDIA. Also includes updates on the valuation of MONSANTO INDIA.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More